Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | DTYMK | P23919 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12685166 | 0.83 | POLB (0.41) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL30728434 | 0.83 | POLB (0.47) | POLBNR1H2GPR119NR1H3KDM4E | |
| SCHEMBL30728432 | 0.82 | NR1H2 (0.41) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL21147683 | 0.82 | POLB (0.41) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL14873918 | 0.82 | POLB (0.41) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL28502078 | 0.82 | POLB (0.41) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL4486033 | 0.80 | NR1H2 (0.40) | POLBNR1H2GPR119NR1H3KDM4E | |
| SCHEMBL18741314 | 0.80 | POLB (0.39) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL1743588 | 0.80 | POLB (0.39) | POLBNR1H2CA12CA9GPR119 | |
| SCHEMBL40961 | 0.79 | NR1H2 (0.54) | NR1H2CA12CA9NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | CBD SOLUTIONS AB (SE) | 2021-05-13 | — | — | US | disclosed |
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | CBD SOLUTIONS AB (SE) | 2021-05-13 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-10285982-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-8946445-B2 | Heterocyclic molecules as apoptosis inducers | Nanjing Allgen Pharma Co., Ltd. (CN) | 2015-02-03 | — | — | US | disclosed |
| US-20140256768-A1 | HETEROCYCLIC MOLECULES AS APOPTOSIS INDUCERS | BETA PHARMA CANADA INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140256768-A1 | HETEROCYCLIC MOLECULES AS APOPTOSIS INDUCERS | BETA PHARMA CANADA INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140256768-A1 | HETEROCYCLIC MOLECULES AS APOPTOSIS INDUCERS | BETA PHARMA CANADA INC. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| WO-2013053045-A1 | HETEROCYCLIC MOLECULES AS APOPTOSIS INDUCERS | BETA PHARMA CANADA INC. (CA) | 2013-04-18 | — | — | WO | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | POLB 1912/4885NR1H2 3796/4885CA12 4401/4885 |
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | MAPT, PSEN1, PSEN2 | POLB 3765/4885NR1H2 1439/4885CA12 707/4885 |
| US-10285982-B2 | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | POLB 1811/4885NR1H2 3786/4885CA12 4762/4885 |
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | POLB 3697/4885NR1H2 678/4885CA12 263/4885 |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | POLB 3899/4885NR1H2 157/4885CA12 2102/4885 |
| US-20140256768-A1 | HETEROCYCLIC MOLECULES AS APOPTOSIS INDUCERS | BAX, BCL2, BAD | POLB 2010/4885NR1H2 1930/4885CA12 3929/4885 |
| US-10350199-B2 | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | POLB 1638/4885NR1H2 2498/4885CA12 4790/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | POLB 1915/4885NR1H2 3732/4885CA12 4431/4885 |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | POLB 3899/4885NR1H2 157/4885CA12 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.